| |
September 30- October 1, 2024| Boston, MA Join us at the Fierce New Product Planning Summit, the premier conference for life science professionals making informed, value-based, data-driven decisions about pipeline products. Experts gather annually to discuss resource utilization and key questions for commercial success.Register now! Save up to $200 when you use the code SUPER to unlock our Super Early Bird Rates. 
|
|
Today’s Big NewsJul 2, 2024 |
|
September 30- October 1, 2024 | Boston, MA Join the Fierce Biotech Summit to explore biotech's recovery and future. This two-day event features leaders discussing biotech IPOs, cell therapy, regulatory challenges, and strategic innovations. Connect with experts and gain valuable industry insights. Grab your pass today! 
|
|
| By Nick Paul Taylor Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis. But the biotech’s victory came on a primary endpoint it changed in May and in a population that excluded the 25% of participants treated at community clinics. |
|
|
|
By James Waldron Crosswalk Therapeutics has strolled over to Codexis to pick up Fabry and Pompe disease compounds that remain from an abandoned Takeda collaboration. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By James Waldron Moderna has become the latest biopharma to benefit from the U.S. Department of Health and Human Services’ concerns about avian flu, awarding the company $176 million to fund the clinical development of a potential vaccine. |
|
July 8-9, 2024 | Jersey City, NJ Hear the latest industry trends from leaders in the field, and developed with input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself.
Save $200 when you Register Today! .png)
|
|
By Nick Paul Taylor Annovis Bio has published its delayed phase 3 Parkinson’s disease data, reporting success in subgroups and secondary endpoints while skirting the question of whether the candidate moved the needle on the main goal. |
By Helen Floersh Mouse models of GBA1 Parkinson’s disease that are treated with Gain Therapeutics’ clinical-stage drug GT-02287 appear to have better cognitive function and lower disease biomarkers than untreated animals, new data show. |
By Helen Floersh CROs aiming to get into the decentralized trials game in the U.S. may find the biggest opportunity in the Great Plains and on Native American reservations—parts of the country with high disease prevalence but where patients would have to travel long distances to take part in a clinical trial, a new Milken Institute report suggests. |
By Andrea Park Under federal law, former FDA employees are prohibited from engaging in certain lobbying activities—but an investigation published in the BMJ on Monday claims that the agency’s staffers are often advised of loopholes in those regulations on their way out the door. |
By Angus Liu In a major win for J&J and Legend, their star CAR-T therapy Carvykti showed it can prolong the lives of patients with previously treated multiple myeloma. |
By Andrea Park For its latest celebrity partnership, Pfizer went in a “Fabulous” direction. |
Fierce podcasts Don’t miss an episode |
| In today’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest biopharma acquisitions in recent years. |
|
|---|
|
|
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
eBook In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
